Indian Pharmacy Law, Statutory Rules, Schedules & Regulatory Compendium
Organised reference to the principal Acts of Parliament, subordinate Rules, statutory Regulations, Price Control Orders, and Gazette Notifications governing pharmacy education, professional practice, drug manufacturing and retail dispensing, narcotic controls, medical devices, clinical trials, cosmetics, and nutraceuticals in India.
Browse by Legal & Regulatory Group (Groups A–F)
A. Pharmacy Profession & Education
Pharmacy Act, 1948; Pharmacy Practice Regulations, 2015; PCI Education Regulations (ER 2020 / B.Pharm / Pharm.D)
The Pharmacy Act, 1948 (Act No. 8 of 1948)
Summary: Primary central statute regulating the profession and practice of pharmacy in India by constituting the Pharmacy Council of India (Central Council) and State Pharmacy Councils, prescribing minimum uniform Education Regulations, and maintaining Central and State Registers of qualified pharmacists.
Relevance to Indian Pharmacy Practice: Defines who may legally practise pharmacy and compound/dispense medicines under Section 42; governs pharmacist registration (First & Subsequent Registers) and professional misconduct removal.
Key Sections, Rules & Schedules: Sec 3–19 (Central Council / PCI), Sec 10 (Education Regulations), Sec 12 (Approval of courses/exams), Sec 15A (Central Register), Sec 19–28 (State & Joint State Councils), Sec 29–40 (Registration of Pharmacists), Sec 42 (Dispensing by unregistered persons prohibited).
The Pharmacy Practice Regulations, 2015
Summary: Statutory regulations framed by the Pharmacy Council of India under Sections 10 and 18 of the Pharmacy Act, 1948 establishing professional practice standards, Code of Pharmacy Ethics, patient counselling duties, and prescription auditing across hospital and community pharmacies.
Relevance to Indian Pharmacy Practice: Mandates display of original Registration Certificate in the pharmacy, white apron with name badge, prescription legality review, patient medication records, and Continuing Pharmacy Education (CPE) for license renewal.
Key Sections, Rules & Schedules: Reg 3 (Code of Pharmacy Ethics), Reg 4 (Duties of Registered Pharmacist to patients & profession), Reg 6 (Inspection of pharmacy premises by Pharmacy Inspector), Reg 8 (Prescription handling & counselling), Appendix I–III.
PCI Education Regulations (ER 2020 for D.Pharm, B.Pharm Regulations 2014 & Pharm.D Regulations 2008)
Summary: Prescribes the minimum qualification for admission, curriculum, practical training (500 hours over 3 months in hospital/community pharmacy for D.Pharm under ER 2020; 1-year internship in Year 6 for Pharm.D), examination standards, and institution approval requirements.
Relevance to Indian Pharmacy Practice: Establishes academic and clinical clerkship benchmarks for D.Pharm, B.Pharm, M.Pharm, and Pharm.D graduates entering Indian hospital, clinical, industrial, and community practice.
Key Sections, Rules & Schedules: Education Regulations, 2020 (D.Pharm Part I, II & Part III Practical Training); Bachelor of Pharmacy (B.Pharm) Course Regulations, 2014; Pharm.D Regulations, 2008.
B. Drug Manufacture, Sale & Distribution
Drugs and Cosmetics Act, 1940; Drugs Rules, 1945 (Schedules C–X); Revised Schedule M (2023); Drugs and Magic Remedies Act, 1954
The Drugs and Cosmetics Act, 1940 (Act No. 23 of 1940)
Summary: Foundational central Act regulating the import, manufacture, distribution, and sale of drugs (Allopathic, ASU, Homoeopathic) and cosmetics in India to prevent substandard, misbranded, adulterated, or spurious products from reaching the public.
Relevance to Indian Pharmacy Practice: Establishes the Drugs Technical Advisory Board (DTAB, Sec 5), Central Drugs Laboratory (CDL, Sec 6), Drugs Consultative Committee (DCC, Sec 7), Central/State Drug Inspectors (Sec 21–22), and strict offences/penalties for spurious or adulterated drugs (Sec 13, 27, 33EEC).
Key Sections, Rules & Schedules: Chapter II (DTAB, CDL, DCC), Chapter III (Import of Drugs & Cosmetics — Sec 8–15), Chapter IV (Manufacture, Sale & Distribution — Sec 16–33A; Sec 17 Misbranded, Sec 17A Adulterated, Sec 17B Spurious), Chapter IVA (Ayurvedic, Siddha & Unani Drugs — Sec 33B–33O).
The Drugs Rules, 1945 (Including Schedules C/C1, G, H, H1, K, M, P, X)
Summary: Comprehensive subordinate rules framed under the Drugs and Cosmetics Act, 1940 governing retail/wholesale sale licenses (Forms 20, 21, 20B, 21B, 20F, 21F), prescription dispensing conditions (Rule 65), labelling standards (Rules 96–97), and statutory Schedules.
Relevance to Indian Pharmacy Practice: Directly governs daily pharmacy operations: Rule 65 mandates qualified pharmacist supervision, prescription register maintenance, 3-year Schedule H1 retention, and 2-year Schedule X duplicate prescription retention.
Key Sections, Rules & Schedules: Part VI (Sale of Drugs — Rules 59–67; Rule 65 Condition of Licences), Part VII (Manufacture for Sale — Rules 68–84), Part IX (Labelling & Packing — Rules 94–106), Schedule C/C1 (Biologicals), Schedule G (Medical Supervision Caution), Schedule H (Prescription Drugs), Schedule H1 (46 Restricted Antibiotics/Anti-TB/Habit-Forming Drugs), Schedule K (Household/Exemptions), Schedule M (GMP), Schedule P (Life Period & Storage), Schedule X (Narcotic/Psychotropic Control).
Revised Schedule M Notification (G.S.R. 922(E)) & Top-300 QR Code Labelling Mandate (G.S.R. 823(E))
Summary: Major statutory notifications upgrading Schedule M from basic GMP to comprehensive Pharmaceutical Quality System (PQS / WHO-GMP alignment with stability testing, product quality review, and computerised system validation) and mandating track-and-trace Barcodes/QR Codes on India's top 300 drug brands.
Relevance to Indian Pharmacy Practice: Strengthens batch-level supply-chain authenticity verification at retail pharmacies (via QR code scanning) and enforces WHO-aligned manufacturing quality across Indian pharmaceutical plants.
Key Sections, Rules & Schedules: Schedule M Parts I–XIII (PQS, QA, HVAC, Water Systems, Qualification & Validation); Rule 96(1)(xii) Schedule H2 Top-300 Brand QR Code Authentication.
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (Act No. 21 of 1954)
Summary: Prohibits misleading advertisements of drugs and magic remedies claiming to procure miscarriage, improve sexual potency, correct menstrual disorders, or cure any of the 54 scheduled diseases and conditions (such as cancer, diabetes, blindness, epilepsy, leukoderma, obesity, or paralysis).
Relevance to Indian Pharmacy Practice: Protects patients from fraudulent 'miracle cure' advertisements across print, packaging, and digital media; distinguishes scientific healthcare communication from prohibited commercial disease-cure claims.
Key Sections, Rules & Schedules: Sec 3 (Prohibition of advertisement of certain drugs for treatment of 54 scheduled diseases), Sec 4 (Prohibition of misleading advertisements relating to drugs), Sec 5 (Prohibition of advertisement of magic remedies), Schedule (54 Diseases/Conditions).
C. Controlled Medicines & Narcotics
NDPS Act, 1985; NDPS (Third Amendment) Rules, 2015 — Essential Narcotic Drugs (ENDs) & Recognized Medical Institutions (RMIs)
The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 (Act No. 61 of 1985)
Summary: Consolidates and amends the law relating to narcotic drugs (opium, morphine, codeine, thebaine, coca derivatives, cannabis) and psychotropic substances (listed in the Schedule to the Act), prohibiting illicit trafficking while providing a unified national framework for medical and scientific access.
Relevance to Indian Pharmacy Practice: Governs hospital and institutional custody, double-lock narcotic storage, small vs commercial quantity thresholds, and strict penalties for unauthorised diversion of opioids and psychotropic medicines.
Key Sections, Rules & Schedules: Sec 2 (Definitions: Coca, Cannabis, Opium, Essential Narcotic Drugs, Psychotropic Substance), Sec 8 (Prohibition of certain operations except for medical/scientific purposes), Sec 9 (Power of Central Govt to permit, control & regulate), Sec 15–32 (Offences and Penalties), Schedule (List of Psychotropic Substances).
NDPS (Third Amendment) Rules, 2015 — Essential Narcotic Drugs (ENDs) & Recognized Medical Institutions (RMIs)
Summary: Notifies six opioids — Morphine, Fentanyl, Methadone, Codeine, Hydrocodone, and Oxycodone — as Essential Narcotic Drugs (ENDs) and replaces fragmented State excise barriers with a single State Drug Controller approval system for Recognized Medical Institutions (RMIs).
Relevance to Indian Pharmacy Practice: Enables oncology centres, palliative care units, and opioid agonist therapy clinics registered as RMIs to stock and dispense oral morphine, fentanyl patches, and methadone for severe cancer pain without bureaucratic multi-agency licenses.
Key Sections, Rules & Schedules: Chapter IIIA of NDPS Rules, 1985 (Rules 52A–52Z: Possession, transport, dispensing, RMI designation by State Drug Controller, annual returns & prescription retention).
D. Drug Pricing & Essential Medicines
Drugs (Prices Control) Order (DPCO), 2013; NPPA Ceiling Price Regulation & NLEM 2022
The Drugs (Prices Control) Order (DPCO), 2013 & National List of Essential Medicines (NLEM 2022)
Summary: Empowers the National Pharmaceutical Pricing Authority (NPPA) to fix market-based Ceiling Prices for Scheduled Formulations listed in Schedule I (384 drugs across 27 therapeutic categories in NLEM 2022) and limits annual MRP increases of non-scheduled formulations to a maximum of 10% per year.
Relevance to Indian Pharmacy Practice: Retail pharmacists must never sell any Scheduled Formulation above the NPPA Ceiling Price (plus applicable GST) and must display updated price lists under Para 24/25 of DPCO 2013.
Key Sections, Rules & Schedules: Para 4 (Calculation of Ceiling Price of Scheduled Formulations: P(c) = P(s) x (1 + M/100), where Margin M = 16% to retailer), Para 5 (Retail price of new drug), Para 16 (Revision of ceiling price with WPI), Para 20 (Monitoring prices of non-scheduled formulations — <=10% annual cap), Schedule I (NLEM 2022 Formulations).
E. Medical Products & Special Regulatory Areas
Medical Devices Rules, 2017; New Drugs & Clinical Trials (NDCT) Rules, 2019; Cosmetics Rules, 2020; FSSAI Nutraceutical Regulations, 2022
The Medical Devices Rules (MDR), 2017 (Amended 2020)
Summary: Establishes a four-tier risk-based regulatory framework (Class A Low Risk, Class B Low-Moderate Risk, Class C Moderate-High Risk, Class D High Risk) for medical devices and in-vitro diagnostics (IVDs) in India, separate from pharmaceutical drug rules.
Relevance to Indian Pharmacy Practice: Governs registration, quality management systems (ISO 13485 / Fifth Schedule), shelf-life, and retail sale of syringes, glucometers, blood pressure monitors, implants, stents, catheters, and diagnostic kits.
Key Sections, Rules & Schedules: Chapter II (Risk Classification Class A, B, C, D), Chapter IV–V (Manufacture & Import Licensing via SLA for Class A/B and CLA/DCGI for Class C/D), Fifth Schedule (Quality Management System).
The New Drugs and Clinical Trials (NDCT) Rules, 2019
Summary: Supersedes Part XA and Schedule Y of the Drugs Rules, 1945 to provide a modern, comprehensive statutory framework for clinical trials, bioavailability and bioequivalence (BA/BE) studies, Ethics Committee registration, academic clinical trials, and trial-injury compensation.
Relevance to Indian Pharmacy Practice: Defines 'New Drug' (including new chemical entities, modified-release dosage forms, new fixed-dose combinations, and phytopharmaceuticals under Rule 2(1)(w)), expedited review timelines (30 days for India-discovered drugs, 90 days for global trials), and serious adverse event (SAE) reporting within 14 days.
Key Sections, Rules & Schedules: Chapter III (Ethics Committee for Clinical Trial vs Biomedical & Health Research), Chapter IV (Clinical Trial of New Drug & Phytopharmaceuticals), Chapter V (BA/BE Studies), Chapter VI (Compensation for Injury or Death), First to Eighth Schedules.
The Cosmetics Rules, 2020
Summary: Decouples cosmetic regulations from the Drugs Rules, 1945 into a standalone code governing cosmetic import registration, manufacturing licensing (Form Cos-8), Good Manufacturing Practices (Seventh Schedule), labelling (Rule 34), BIS IS 4707 raw material compliance, and prohibition of animal testing.
Relevance to Indian Pharmacy Practice: Draws the statutory line between topical cosmetic skin/hair care products (which clean, condition, or protect superficial appearance) and Schedule H prescription dermatological drugs (such as tretinoin, hydroquinone, or topical corticosteroids).
Key Sections, Rules & Schedules: Chapter III (Import of Cosmetics), Chapter IV (Manufacture of Cosmetics for Sale), Chapter VI (Labelling, Packing & Standards — Rule 34 & BIS IS 4707 Part 1/2), Rule 39 (Prohibition of testing of cosmetics on animals).
FSSAI (Health Supplements, Nutraceuticals, FSDU, FSMP, Functional Food and Novel Food) Regulations, 2022
Summary: Regulates oral health supplements, nutraceuticals, probiotics, and special medical/dietary foods under FSSAI, stipulating that added vitamins and minerals in health supplements must not exceed one ICMR-NIN Recommended Dietary Allowance (RDA) and prohibiting medicinal disease-cure claims.
Relevance to Indian Pharmacy Practice: Clarifies why nutritional supplements (<=1 RDA, carrying an FSSAI License and 'NOT FOR MEDICINAL USE') are legally distinct from therapeutic vitamin/mineral drugs (>1 RDA, such as Cholecalciferol 60,000 IU or Folic Acid 5 mg, regulated under CDSCO).
Key Sections, Rules & Schedules: Sec 22 of FSS Act, 2006; Health Supplements, Nutraceuticals, FSDU, FSMP, Functional Food (Probiotics >=10^8 CFU/serving with strain ID & Prebiotics) and Novel Food provisions.
F. Related Public-Health, IP & Environmental Regulation
Poisons Act, 1919; Bio-Medical Waste Management Rules, 2016; Indian Patents Act, 1970 (Sec 3(d), Sec 84 & Sec 107A)
The Poisons Act, 1919 (Act No. 12 of 1919)
Summary: Regulates the importation, possession for sale, and retail/wholesale sale of scheduled non-medicinal and chemical poisons across India, empowering State Governments to enforce poison possession licenses and sale registers.
Relevance to Indian Pharmacy Practice: Foundational pharmacy jurisprudence statute governing toxic chemical custody, corrosive acid sale restrictions, and poison register traceability.
Key Sections, Rules & Schedules: Sec 2 (Power of State Government to regulate possession for sale and sale of any poison), Sec 3 (Power to prohibit importation into India except under licence), Sec 4 (Power to regulate possession of any poison in certain areas), Sec 6 (Penalty for unlawful importation, possession or sale).
The Bio-Medical Waste Management Rules, 2016 (Amended 2018)
Summary: Mandates 4-colour source segregation (Yellow, Red, White, Blue), barcoding, pretreatment, and environmentally safe disposal of biomedical waste generated by hospitals, clinics, laboratories, and pharmacies.
Relevance to Indian Pharmacy Practice: Expired, discarded, or contaminated medicines — including antibiotics and cytotoxic oncology drugs (Yellow Category) and glass ampoules/vials (Blue Category) — must be segregated and returned via Common Bio-Medical Waste Treatment Facilities (CBWTFs) to prevent environmental AMR and toxic exposure.
Key Sections, Rules & Schedules: Rule 4 (Duties of Occupier), Schedule I (Four Colour Categories: Yellow — Human anatomical, soiled, and expired/discarded medicines & cytotoxic drugs; Red — Contaminated recyclable plastics/tubing; White — Translucent puncture-proof sharps/needles; Blue — Glassware, ampoules, vials & metallic implants).
The Patents Act, 1970 (Pharmaceutical Provisions: Sec 3(d), Sec 84 & Sec 107A)
Summary: Governs pharmaceutical product and process patents in India, balancing innovation incentives with public-health safeguards against 'evergreening' of known molecules and enabling compulsory licensing and generic regulatory R&D.
Relevance to Indian Pharmacy Practice: Section 3(d) prevents patenting of mere new salt, ester, polymorph, or derivative forms of a known substance unless they demonstrate significantly enhanced therapeutic efficacy; Section 84 enables Compulsory Licensing; Section 107A (Bolar Exemption) permits generic BA/BE development prior to patent expiry.
Key Sections, Rules & Schedules: Sec 3(d) (Anti-evergreening efficacy bar), Sec 3(e) (Mere admixture vs synergistic combination), Sec 53 (20-year patent term), Sec 84 (Compulsory Licences), Sec 92A (Compulsory licence for export of patented pharmaceutical products), Sec 107A (Bolar regulatory exception).
Quick Reference: Key Schedules to the Drugs Rules, 1945
| Schedule | Statutory Subject & Scope | Retail Pharmacy & Labelling Requirement |
|---|---|---|
| Schedule C & C(1) | Biological and special products (sera, vaccines, toxins, insulin, parenteral preparations, digitalis, ergot, fish liver oil) | Requires Form 21 / 21B license and cold-chain storage (2°C–8°C where specified). |
| Schedule G | Substances required to be taken only under medical supervision (e.g., certain antihistamines, oral antidiabetics, antineoplastics) | Label must display boxed caution: "Caution: It is dangerous to take this preparation except under medical supervision." |
| Schedule H | Prescription-only medicines (~536 molecules) | Symbol Rx + red vertical line; sold strictly against a valid RMP prescription under Rule 65. |
| Schedule H1 | 46 notified 3rd/4th-gen antibiotics, anti-TB medicines, and selected habit-forming psychotropics/analgesics (G.S.R. 588(E)) | Symbol Rx in red inside red box; mandatory 3-year prescription register retention (patient, prescriber, drug & quantity). |
| Schedule K | Drugs exempted from certain provisions of Chapter IV of the Act and Rules (household remedies, ORS, paracetamol, medical oxygen, physician samples) | Conditional exemptions for sale in original sealed packs under specified conditions. |
| Schedule M | Good Manufacturing Practices (GMP) and requirements of premises, plant, and equipment for pharmaceutical products (Revised Dec 2023) | Mandatory Pharmaceutical Quality System (PQS), stability testing, HVAC, and validation for manufacturers. |
| Schedule P | Life period (shelf-life in months) and storage temperature conditions of drugs | Pharmacies must maintain specified storage conditions (e.g., Cold place 2°C–8°C; Cool place 8°C–25°C) and never sell expired stock. |
| Schedule X | High-abuse-potential psychotropic and barbiturate/anaesthetic drugs (e.g., Ketamine, Secobarbital, Amobarbital) | Symbol NRx in red; requires separate Form 20F/21F license, lock-and-key storage, and 2-year retention of duplicate prescription. |